title: Anticoagulation Reversal Strategies for Left Ventricular Assist Device Patients Presenting with Acute Intracranial Hemorrhage.
abstract: The safety of alternative vitamin K antagonist (VKA) reversal strategies in patients with left ventricular assist devices (LVAD's) who present with intracranial hemorrhage (ICH) are not well known. A review of LVAD patients with ICH from May 2008 to 2015 was conducted, comparing the safety and efficacy of 4-factor prothrombin complex concentrate-assisted VKA reversal (4F-PCC group, n = 10) to reversal with traditional agents alone (no-PCC group, n = 10). An analysis of a no-reversal strategy in selected patients (n = 11) with ICH was additionally performed. Thirty-one cases of ICH on LVAD support were reviewed. The rate of post reversal thromboembolic events was not significantly different between 4F-PCC and no-PCC patients (0% vs. 10%, p = 1.0); however, the time to VKA reversal was shorter (474 vs. 945 minutes, p = 0.02) and fresh frozen plasma (FFP) requirements lower (1.9 vs. 3.6 units, p = 0.05) in 4F-PCC patients, with no difference in mortality between groups (p = 1.0). Eleven patients (mean ICH volume: 0.4 cm) were successfully managed without active VKA reversal, with no increased hemorrhage noted on neuroimaging. These results suggest that 4F-PCC-assisted reversal in LVAD patients is safe and may improve the efficacy of VKA reversal. Our findings also indicate that carefully selected patients with small ICH volumes may be safely managed by discontinuing anticoagulation and allowing the international normalized ratio (INR) to normalize physiologically.
authors.affiliation: From the *Division of Cardiac Surgery, †Department of Medicine, Hematology/Oncology, and ‡Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York.
authors.forename: Joshua K
authors.initials: JK
authors.lastname: Wong
authors.forename: Peter C
authors.initials: PC
authors.lastname: Chen
authors.forename: Jennifer
authors.initials: J
authors.lastname: Falvey
authors.forename: Amber L
authors.initials: AL
authors.lastname: Melvin
authors.forename: Alcina K
authors.initials: AK
authors.lastname: Lidder
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Lowenstein
authors.forename: Amrendra S
authors.initials: AS
authors.lastname: Miranpuri
authors.forename: Peter A
authors.initials: PA
authors.lastname: Knight
authors.forename: H Todd
authors.initials: HT
authors.lastname: Massey
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D005260:Female; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D019934:International Normalized Ratio; D020300:Intracranial Hemorrhages / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; D014812:Vitamin K; C025667:prothrombin complex concentrates